CA2295740A1 - Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn - Google Patents

Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn Download PDF

Info

Publication number
CA2295740A1
CA2295740A1 CA002295740A CA2295740A CA2295740A1 CA 2295740 A1 CA2295740 A1 CA 2295740A1 CA 002295740 A CA002295740 A CA 002295740A CA 2295740 A CA2295740 A CA 2295740A CA 2295740 A1 CA2295740 A1 CA 2295740A1
Authority
CA
Canada
Prior art keywords
antigen
vector
virus
submicron oil
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002295740A
Other languages
English (en)
Inventor
Gary Van Nest
Douglas J. Jolly
James E. Mccormak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2295740A1 publication Critical patent/CA2295740A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Cette invention concerne l'utilisation d'émulsions huile dans eau submicroniques avec des techniques d'immunisation par acides nucléiques. Le procédé comprend l'immunisation avec des compositions vaccinales contenant des molécules d'acides nucléiques codant au moins un antigène spécifique, ainsi que l'administration d'un adjuvant huile dans eau submicronique tel que MF59. L'adjuvant peut être administré avant, après ou bien en même temps que les vaccins à base d'acides nucléiques.
CA002295740A 1997-07-08 1998-07-08 Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn Abandoned CA2295740A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5194497P 1997-07-08 1997-07-08
US60/051,944 1997-07-08
US5475697P 1997-08-05 1997-08-05
US60/054,756 1997-08-05
PCT/US1998/014310 WO1999002132A2 (fr) 1997-07-08 1998-07-08 Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn

Publications (1)

Publication Number Publication Date
CA2295740A1 true CA2295740A1 (fr) 1999-01-21

Family

ID=26729981

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002295740A Abandoned CA2295740A1 (fr) 1997-07-08 1998-07-08 Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn

Country Status (5)

Country Link
EP (1) EP1006999A2 (fr)
JP (1) JP2002509545A (fr)
AU (1) AU8298298A (fr)
CA (1) CA2295740A1 (fr)
WO (1) WO1999002132A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2875700A (en) * 1999-02-26 2000-09-14 Chiron Corporation Microemulsions with adsorbed macromoelecules and microparticles
EA006233B1 (ru) 1999-05-13 2005-10-27 Уайт Холдингз Корпорейшн Комбинированные адъювантные композиции для усиления иммунного ответа у позвоночного животного
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
GB0622282D0 (en) 2006-11-08 2006-12-20 Novartis Ag Quality control methods
WO2009120811A1 (fr) * 2008-03-25 2009-10-01 Juvaris Biotherapeutics, Inc. Amélioration d’une réponse immunitaire par l’administration d’un complexe adn-lipide cationique (cldc)
GB0822001D0 (en) * 2008-12-02 2009-01-07 Glaxosmithkline Biolog Sa Vaccine
MX2012011340A (es) * 2010-03-29 2012-11-16 Novartis Ag Composicion que comprende el peptido amiloide beta 1-6acoplado a una particula similar a virus y un auxiliar.
JP6025721B2 (ja) 2010-07-06 2016-11-16 ノバルティス アーゲー カチオン性水中油型エマルジョン
MX350198B (es) 2011-07-06 2017-08-30 Novartis Ag Emulsiones aceite en agua que contienen acidos nucleicos.
WO2013006837A1 (fr) 2011-07-06 2013-01-10 Novartis Ag Emulsions huile dans eau cationiques

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU212924B (en) * 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
ATE302854T1 (de) * 1993-01-26 2005-09-15 Univ Pennsylvania Zusammensetzungen und verfahren zur verabreichung von genetischem material
JPH10501136A (ja) * 1994-06-02 1998-02-03 カイロン コーポレイション ウイルスに基づく感染／トランスフェクションシステムを用いる核酸免疫化

Also Published As

Publication number Publication date
AU8298298A (en) 1999-02-08
JP2002509545A (ja) 2002-03-26
WO1999002132A2 (fr) 1999-01-21
WO1999002132A3 (fr) 1999-08-12
EP1006999A2 (fr) 2000-06-14

Similar Documents

Publication Publication Date Title
EP0971738B1 (fr) Mutants detoxifies de toxines bacteriennes ribolysant l'adp utilises comme adjuvants parenteraux
Hasan et al. Nucleic acid immunization: concepts and techniques associated with third generation vaccines
Gregoriadis Genetic vaccines: strategies for optimization
US6355247B1 (en) Nucleic acid immunization using a virus-based infection/transfection system
EP0596032B2 (fr) Induction de reponses de lymphocytes t cytotoxiques
US8609109B2 (en) HIV vaccine formulations
EP1119630B1 (fr) Produits de recombinaison d'acide nucleique pour immunisation genetique
Dyall et al. CD4-independent in vivo priming of murine CTL by optimal MHC class I-restricted peptides derived from intracellular pathogens
CA2295740A1 (fr) Utilisation d'emulsions huile dans eau submicroniques avec des vaccins a adn
MXPA04005770A (es) Metodos para la inmunizacion con polinucleotidos asistida por particulas utilizando un campo electrico de impulsos.
Lomada et al. A two-codon mutant of cholera toxin lacking ADP-ribosylating activity functions as an effective adjuvant for eliciting mucosal and systemic cellular immune responses to peptide antigens
Vajdy Current efforts on generation of optimal immune responses against HIV through mucosal immunisations
US6881723B1 (en) Nucleic acid constructs
JP2017512499A (ja) モザイクｈｉｖ−１配列およびその使用
AU771286B2 (en) Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
EP1486215A2 (fr) Mutants détoxifies de toxines bactériennes ribolysant l'ADP utilisés comme adjuvants parentéraux
Berzofsky et al. Design of engineered vaccines for HIV
Newman et al. Characterization of Immune Responses Elicited by an Experimental Facilitated-DNA Vaccine for Human Immunodeficiency Virus Type-1 (HIV-1)
ZA200305348B (en) Nucleic acid mucosal immunization.

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead